Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia

Bone Marrow Transplantation volume 56, pages 508–510 (2021)Cite this article

Subjects

This article has been updated

The role of hematopoietic stem cell transplantation (HCT) for patients with acute myeloid leukemia (AML) has expanded significantly. The conditioning regimen plays a crucial role in the transplant process with the goal of providing immunosuppression to prevent rejection of the transplanted graft and eliminating the underlying disease for which the transplant is being performed. Patients traditionally receive either myeloablative (MA) or non-myeloablative/reduced intensity conditioning (RIC) regimens [1], the latter mainly used in patients with multiple co-morbidities deemed less likely to tolerate MA with studies demonstrating similar disease-free survival and non-relapse mortality (NRM) [2, 3].

Cardiovascular disease is common in patients undergoing HCT [4, 5]; however, the reporting of adverse cardiovascular events (ACEs) in this patient cohort remains sparse, with no studies directly comparing cardiovascular outcomes between MA and RIC regimens. Our study set to evaluate these outcomes with the aim of being able to provide further guidance to cardiologists and hematologists who are involved in risk stratification prior to HCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cumulative incidence of adverse cardiovascular events.

Change history

  • 23 August 2020

    The original online PDF version of the Article presented Figure 1 in colour. It now appears in monochrome in the PDF version of the Article.

References

  1. Horan JT, Logan BR, Agovi-Johnson M-A, Lazarus HM, Bacigalupo AA, Ballen KK, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29:805.

    Article  Google Scholar 

  2. Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035–44.

    Article  Google Scholar 

  3. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154.

    Article  Google Scholar 

  4. Tonorezos ES, Stillwell EE, Calloway JJ, Glew T, Wessler JD, Rebolledo BJ, et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:1212.

    Article  CAS  Google Scholar 

  5. Blaes A, Konety S, Hurley P. Cardiovascular complications of hematopoietic stem cell transplantation. Curr Treat Options Cardiovasc Med. 2016;18:25.

    Article  Google Scholar 

  6. Feijen EA, Leisenring WM, Stratton KL, Ness KK, Van Der Pal HJ, Caron HN, et al. Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer. J Clin Oncol. 2015;33:3774.

    Article  CAS  Google Scholar 

  7. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452.

    Article  CAS  Google Scholar 

  8. Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ET. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol. 2017;70:2536–51.

    Article  Google Scholar 

  9. Rashidi A, Ebadi M, Colditz GA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2016;22:651–7.

    Article  Google Scholar 

  10. Aoki J, Kanamori H, Tanaka M, Yamasaki S, Fukuda T, Ogawa H, et al. Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol. 2016;91:302–7.

    Article  Google Scholar 

  11. Hurley P, Konety S, Cao Q, Weisdorf D, Blaes A. Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done? Biol Blood Marrow Transplant. 2015;21:300–4.

    Article  Google Scholar 

  12. Sarmiento M, Parody R, Márquez-Malaver F, Espigado I, Falantes J, Caballero T, et al. Pre-transplant diastolic but not systolic dysfunction has a negative prognostic impact after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:863–5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Disease, Vanderbilt University Medical Center, Nashville, TN, USA

    Majd A. El-Harasis

  2. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    Mehrdad Hefazi, William J. Hogan, Mark R. Litzow & Mrinal M. Patnaik

  3. Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

    Raghav Julakanti

  4. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA

    Joerg Herrmann

Authors
  1. Majd A. El-Harasis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehrdad Hefazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raghav Julakanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William J. Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark R. Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mrinal M. Patnaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joerg Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Majd A. El-Harasis.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Harasis, M.A., Hefazi, M., Julakanti, R. et al. Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 56, 508–510 (2021). https://doi.org/10.1038/s41409-020-01021-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-01021-y

Search

Advanced search

Quick links